ArticleMolecular therapy. Oncology2026
Engineering "off-the-shelf" TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive T cell therapy using T cell receptor (TCR)-engineered T (TCR-T) cells shows promise for the treatment of cancer. Our lab employs mRNA electroporation to redirect T cell specificity toward HBV antigens expressed on HBV-related HCC, while exploiting mRNA's transient nature to limit toxicity. Here, we first demonstrated that peripheral blood mononuclear cells (PBMCs) from solid cancer patients are inferior manufacturing sources compared with healthy donors, showing reduced manufacturability and lower naive T cell frequencies. Since these limitations necessitate shifting to allogeneic "off-the-shelf" TCR-T products from healthy donors, we developed a non-gene-editing platform to produce such TCR-T cells. We addressed host-versus-graft rejection by combining transient tacrolimus-induced immunosuppression with immunosuppressive drug-resistant armored (IDRA) TCR-T cells. To reduce the risk of graft-versus-host disease, we optimized manufacturing using an IL-2/4/7 cytokine cocktail. The resulting TCR-T cells exhibited reduced alloreactivity, a less NK-like phenotype, and elevated IL-4/IL-10 secretion, while maintaining robust antigen-specific cytotoxicity and migratory capacity. This study provides an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.